menu search

89bio to present additional pegozafermin data in severe hypertriglyceridemia from phase 2 entrigue study at american college of cardiology's annual scientific session together with world congress of c

SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...

February 21, 2023, 8:00 am

89bio to present additional pegozafermin data in severe hypertriglyceridemia from phase 2 entrigue study at american college of cardiology's annual scientific session together with world congress of c

SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...

February 21, 2023, 8:00 am

This analyst thinks 89bio's pegozafermin data has exceeded expectations

In June, 89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of ...

July 11, 2022, 2:24 pm

89bio posts promising pegozafermin data for severe hypertriglyceridemia

89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pego...

June 29, 2022, 6:07 am


Search within

Pages Search Results: